Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
MESOBLAST LIMITED (MSB)ASX AI Signals has generated 0 signals for MSB during the last 90 days, indicating low trading activity
MSB Share Price | |
| Current Price | $2.060 |
| 52 Week High | $3.070 |
| 52 Week Low: | $1.575 |
| Trading at (% of 52 Week High) | 67.10% |
Mesoblast Limited (ASX: MSB) is a leading biotechnology company that develops innovative cellular medicines using mesenchymal lineage adult stem cells. The company focuses on treatments for inflammatory diseases, cardiovascular conditions, and orthopedic disorders. Mesoblast conducts research and commercial partnerships worldwide to advance its pipeline of regenerative therapies.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
Mesoblast Limited
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Admi Mesoblast Limited
Optimized capital structure, retiring short-term maturing debt
Well-funded for commercial operations and growth pipeline
NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases Mesoblast Limited
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive’s A Mesoblast Limited
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host Mesoblast Limited
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has aLatest MESOBLAST LIMITED(MSB) News
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial